ESOC 2022
Lys Therapeutics announces to attend the 8th European Stroke Organisation Conference (ESOC 2022, 4-6 May 2021, LYON France).
Dr. Manuel BLANC, Pr. Denis VIVIEN, Dr. Flavie Lesept and Dr. Fanny Potzeha are happy to meet you there.
💪 All together against Stroke and its dramatic consequences.
Oral presentation – ESOC 2022
🎤 *Pr. Denis VIVIEN*, head of the bb@c, Blood and Brain Caen normandie Institute and Head of Science of Lys Therapeutics is presenting today new promising preclinical data during the 8th European Stroke Organisation Conference (#ESOC2022) with our lead candidate Glunomab in ischemic stroke including with diabetes, an important comorbidity among stroke patients :
To be followed today at 5pm, physically and in digital during #ESOC2022 conference in the #EAN–#ESO Joint Symposium: “The vascular side of neurodegeneration: a preclinical and clinical perspective”
Scientific poster – ESOC 2022
Lys Therapeutics is reinforcing its neurovascular business unit with new promising preclinical data presented during the 8th European Stroke Organisation Conference (#ESOC2022) for its lead candidate Glunomab in ischemic stroke including with diabetes, an important comorbidity among stroke patients.
#ESOC2022 #ESO #EAN #Science #Stroke #neurosciences #clinicaltrials #Research #PublicPrivatePartnership #Collaboration #deeptech #biotech #healthcare #lifesciences #CNS #brain #NeurologicalDiseases #NeurovascularDisorders #stroke #neurodegeneration #innovation #MedicalNeeds #LysTherapeutics #biotherapy #Glunomab #Glunozumab
Dr. Manuel BLANC, Pr. Denis VIVIEN, Dr. Flavie Lesept, Dr. Fanny Potzeha and Florent Lebrun are happy to meet you there.